News | May 16, 2021
Govt. to augment Covaxin production by 10 crore doses
Financial support is being provided as a grant from the Government of India
Financial support is being provided as a grant from the Government of India
Lurasidone Hydrochloride tablets are also indicated for adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder
The company is working closely with its six manufacturing partners in India
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
The agreement will help ensure wider reach and access to patients in India
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Subscribe To Our Newsletter & Stay Updated
